



Tuberculosis Vaccine Treatment Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	129	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette–Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.

Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.

In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.

The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.

Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.

Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.

Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.

Report Scope

This report quantifies the global Tuberculosis Vaccine Treatment market in terms of revenue (US\$ million) and, where applicable, sales volume (K Dose), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Dose) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tuberculosis Vaccine Treatment Market by Company

Merck

Japan BCG Lab

Serum Institute of India

AJ Vaccines

BioFarma

GreenSignal Bio Pharma

China National Biotec

Biomed Lublin

Taj Pharmaceuticals

Ataulpho de Paiva

IVAC

Queen Saovabha Mem. Inst

Microgen

Tuberculosis Vaccine Treatment Segment by Type

Immune Vaccine

Therapy Vaccine

Tuberculosis Vaccine Treatment Segment by Application

Self-Procurement

UNICEF

Other

Tuberculosis Vaccine Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Tuberculosis Vaccine Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Tuberculosis Vaccine Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Tuberculosis Vaccine Treatment Market Size (2021-2032)
 - 2.2.2 Global Tuberculosis Vaccine Treatment Sales (2021-2032)
 - 2.2.3 Global Tuberculosis Vaccine Treatment Market Average Price (2021-2032)
- 2.3 Tuberculosis Vaccine Treatment by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Immune Vaccine
 - 2.3.3 Therapy Vaccine
- 2.4 Tuberculosis Vaccine Treatment by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Self-Procurement
 - 2.4.3 UNICEF
 - 2.4.4 Other

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Tuberculosis Vaccine Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tuberculosis Vaccine Treatment Sales (K Dose) of Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Vaccine Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Vaccine Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Tuberculosis Vaccine Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tuberculosis Vaccine Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tuberculosis Vaccine Treatment, Product Type & Application
- 3.8 Global Manufacturers of Tuberculosis Vaccine Treatment, Established Date
- 3.9 Global Tuberculosis Vaccine Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Merck
 - 4.1.1 Merck Company Information
 - 4.1.2 Merck Business Overview
 - 4.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Merck Tuberculosis Vaccine Treatment Product Portfolio
 - 4.1.5 Merck Recent Developments
- 4.2 Japan BCG Lab

- 4.2.1 Japan BCG Lab Company Information
- 4.2.2 Japan BCG Lab Business Overview
- 4.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Portfolio
- 4.2.5 Japan BCG Lab Recent Developments
- 4.3 Serum Institute of India
 - 4.3.1 Serum Institute of India Company Information
 - 4.3.2 Serum Institute of India Business Overview
 - 4.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Portfolio
 - 4.3.5 Serum Institute of India Recent Developments
- 4.4 AJ Vaccines
 - 4.4.1 AJ Vaccines Company Information
 - 4.4.2 AJ Vaccines Business Overview
 - 4.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Portfolio
 - 4.4.5 AJ Vaccines Recent Developments
- 4.5 BioFarma
 - 4.5.1 BioFarma Company Information
 - 4.5.2 BioFarma Business Overview
 - 4.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 BioFarma Tuberculosis Vaccine Treatment Product Portfolio
 - 4.5.5 BioFarma Recent Developments
- 4.6 GreenSignal Bio Pharma
 - 4.6.1 GreenSignal Bio Pharma Company Information
 - 4.6.2 GreenSignal Bio Pharma Business Overview
 - 4.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Portfolio
 - 4.6.5 GreenSignal Bio Pharma Recent Developments
- 4.7 China National Biotec
 - 4.7.1 China National Biotec Company Information
 - 4.7.2 China National Biotec Business Overview
 - 4.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Portfolio
 - 4.7.5 China National Biotec Recent Developments
- 4.8 Biomed Lublin
 - 4.8.1 Biomed Lublin Company Information
 - 4.8.2 Biomed Lublin Business Overview
 - 4.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Portfolio
 - 4.8.5 Biomed Lublin Recent Developments
- 4.9 Taj Pharmaceuticals
 - 4.9.1 Taj Pharmaceuticals Company Information
 - 4.9.2 Taj Pharmaceuticals Business Overview
 - 4.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
 - 4.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Portfolio
 - 4.9.5 Taj Pharmaceuticals Recent Developments
- 4.10 Ataulpho de Paiva

- 4.10.1 Ataulpho de Paiva Company Information
- 4.10.2 Ataulpho de Paiva Business Overview
- 4.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Portfolio
- 4.10.5 Ataulpho de Paiva Recent Developments

4.11 IVAC

- 4.11.1 IVAC Company Information
- 4.11.2 IVAC Business Overview
- 4.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 IVAC Tuberculosis Vaccine Treatment Product Portfolio
- 4.11.5 IVAC Recent Developments

4.12 Queen Saovabha Mem. Inst

- 4.12.1 Queen Saovabha Mem. Inst Company Information
- 4.12.2 Queen Saovabha Mem. Inst Business Overview
- 4.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Portfolio
- 4.12.5 Queen Saovabha Mem. Inst Recent Developments

4.13 Microgen

- 4.13.1 Microgen Company Information
- 4.13.2 Microgen Business Overview
- 4.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Microgen Tuberculosis Vaccine Treatment Product Portfolio
- 4.13.5 Microgen Recent Developments

5 Global Tuberculosis Vaccine Treatment Market Scenario by Region

5.1 Global Tuberculosis Vaccine Treatment Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Tuberculosis Vaccine Treatment Sales by Region: 2021-2032

- 5.2.1 Global Tuberculosis Vaccine Treatment Sales by Region: 2021-2026
- 5.2.2 Global Tuberculosis Vaccine Treatment Sales by Region: 2027-2032

5.3 Global Tuberculosis Vaccine Treatment Revenue by Region: 2021-2032

- 5.3.1 Global Tuberculosis Vaccine Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Tuberculosis Vaccine Treatment Revenue by Region: 2027-2032

5.4 North America Tuberculosis Vaccine Treatment Market Facts & Figures by Country

- 5.4.1 North America Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.4.3 North America Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico

5.5 Europe Tuberculosis Vaccine Treatment Market Facts & Figures by Country

- 5.5.1 Europe Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain

5.5.10 Netherlands

5.5.11 Switzerland

5.5.12 Sweden

5.5.13 Poland

5.6 Asia Pacific Tuberculosis Vaccine Treatment Market Facts & Figures by Country

5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales by Country (2021-2032)

5.6.3 Asia Pacific Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 Taiwan

5.6.10 Southeast Asia

5.7 South America Tuberculosis Vaccine Treatment Market Facts & Figures by Country

5.7.1 South America Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Tuberculosis Vaccine Treatment Sales by Country (2021-2032)

5.7.3 South America Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)

5.7.4 Brazil

5.7.5 Argentina

5.7.6 Chile

5.8 Middle East and Africa Tuberculosis Vaccine Treatment Market Facts & Figures by Country

5.8.1 Middle East and Africa Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Tuberculosis Vaccine Treatment Sales by Country (2021-2032)

5.8.3 Middle East and Africa Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)

5.8.4 Egypt

5.8.5 South Africa

5.8.6 Israel

5.8.7 Türkiye

5.8.8 GCC Countries

6 Segment by Type

6.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032)

6.1.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032) & (K Dose)

6.1.2 Global Tuberculosis Vaccine Treatment Sales Market Share by Type (2021-2032)

6.2 Global Tuberculosis Vaccine Treatment Revenue by Type (2021-2032)

6.2.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Tuberculosis Vaccine Treatment Revenue Market Share by Type (2021-2032)

6.3 Global Tuberculosis Vaccine Treatment Price by Type (2021-2032)

7 Segment by Application

7.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032)

7.1.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032) & (K Dose)

7.1.2 Global Tuberculosis Vaccine Treatment Sales Market Share by Application (2021-2032)

7.2 Global Tuberculosis Vaccine Treatment Revenue by Application (2021-2032)

7.2.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Tuberculosis Vaccine Treatment Revenue Market Share by Application (2021-2032)

7.3 Global Tuberculosis Vaccine Treatment Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Tuberculosis Vaccine Treatment Value Chain Analysis

8.1.1 Tuberculosis Vaccine Treatment Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Tuberculosis Vaccine Treatment Production Mode & Process

8.2 Tuberculosis Vaccine Treatment Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Tuberculosis Vaccine Treatment Distributors

8.2.3 Tuberculosis Vaccine Treatment Customers

9 Global Tuberculosis Vaccine Treatment Analyzing Market Dynamics

9.1 Tuberculosis Vaccine Treatment Industry Trends

9.2 Tuberculosis Vaccine Treatment Industry Drivers

9.3 Tuberculosis Vaccine Treatment Industry Opportunities and Challenges

9.4 Tuberculosis Vaccine Treatment Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Tuberculosis Vaccine Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Tuberculosis Vaccine Treatment Sales (K Dose) of Manufacturers (2021-2026)
- Table 7: Global Tuberculosis Vaccine Treatment Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Tuberculosis Vaccine Treatment Revenue of Manufacturers (2021-2026)
- Table 9: Global Tuberculosis Vaccine Treatment Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Tuberculosis Vaccine Treatment Average Price (USD/K Dose) of Manufacturers (2021-2026)
- Table 11: Global Tuberculosis Vaccine Treatment Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Tuberculosis Vaccine Treatment, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Tuberculosis Vaccine Treatment, Product Type & Application
- Table 14: Global Tuberculosis Vaccine Treatment Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Tuberculosis Vaccine Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Merck Company Information
- Table 19: Merck Business Overview
- Table 20: Merck Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 21: Merck Tuberculosis Vaccine Treatment Product Portfolio
- Table 22: Merck Recent Developments
- Table 23: Japan BCG Lab Company Information
- Table 24: Japan BCG Lab Business Overview
- Table 25: Japan BCG Lab Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 26: Japan BCG Lab Tuberculosis Vaccine Treatment Product Portfolio
- Table 27: Japan BCG Lab Recent Developments
- Table 28: Serum Institute of India Company Information
- Table 29: Serum Institute of India Business Overview
- Table 30: Serum Institute of India Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 31: Serum Institute of India Tuberculosis Vaccine Treatment Product Portfolio
- Table 32: Serum Institute of India Recent Developments
- Table 33: AJ Vaccines Company Information
- Table 34: AJ Vaccines Business Overview
- Table 35: AJ Vaccines Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 36: AJ Vaccines Tuberculosis Vaccine Treatment Product Portfolio
- Table 37: AJ Vaccines Recent Developments
- Table 38: BioFarma Company Information
- Table 39: BioFarma Business Overview
- Table 40: BioFarma Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 41: BioFarma Tuberculosis Vaccine Treatment Product Portfolio
- Table 42: BioFarma Recent Developments
- Table 43: GreenSignal Bio Pharma Company Information
- Table 44: GreenSignal Bio Pharma Business Overview
- Table 45: GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 46: GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Portfolio
- Table 47: GreenSignal Bio Pharma Recent Developments

- Table 48: China National Biotec Company Information
- Table 49: China National Biotec Business Overview
- Table 50: China National Biotec Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 51: China National Biotec Tuberculosis Vaccine Treatment Product Portfolio
- Table 52: China National Biotec Recent Developments
- Table 53: Biomed Lublin Company Information
- Table 54: Biomed Lublin Business Overview
- Table 55: Biomed Lublin Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 56: Biomed Lublin Tuberculosis Vaccine Treatment Product Portfolio
- Table 57: Biomed Lublin Recent Developments
- Table 58: Taj Pharmaceuticals Company Information
- Table 59: Taj Pharmaceuticals Business Overview
- Table 60: Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 61: Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Portfolio
- Table 62: Taj Pharmaceuticals Recent Developments
- Table 63: Ataulpho de Paiva Company Information
- Table 64: Ataulpho de Paiva Business Overview
- Table 65: Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 66: Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Portfolio
- Table 67: Ataulpho de Paiva Recent Developments
- Table 68: IVAC Company Information
- Table 69: IVAC Business Overview
- Table 70: IVAC Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 71: IVAC Tuberculosis Vaccine Treatment Product Portfolio
- Table 72: IVAC Recent Developments
- Table 73: Queen Saovabha Mem. Inst Company Information
- Table 74: Queen Saovabha Mem. Inst Business Overview
- Table 75: Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 76: Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Portfolio
- Table 77: Queen Saovabha Mem. Inst Recent Developments
- Table 78: Microgen Company Information
- Table 79: Microgen Business Overview
- Table 80: Microgen Tuberculosis Vaccine Treatment Sales (K Dose), Revenue (US\$ Million), Price (USD/K Dose) and Gross Margin (2021-2026)
- Table 81: Microgen Tuberculosis Vaccine Treatment Product Portfolio
- Table 82: Microgen Recent Developments
- Table 83: Global Tuberculosis Vaccine Treatment Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 84: Global Tuberculosis Vaccine Treatment Sales by Region (2021-2026) & (K Dose)
- Table 85: Global Tuberculosis Vaccine Treatment Sales Market Share by Region (2021-2026)
- Table 86: Global Tuberculosis Vaccine Treatment Sales by Region (2027-2032) & (K Dose)
- Table 87: Global Tuberculosis Vaccine Treatment Sales Market Share by Region (2027-2032)
- Table 88: Global Tuberculosis Vaccine Treatment Revenue by Region (2021-2026) & (US\$ Million)
- Table 89: Global Tuberculosis Vaccine Treatment Revenue Market Share by Region (2021-2026)
- Table 90: Global Tuberculosis Vaccine Treatment Revenue by Region (2027-2032) & (US\$ Million)
- Table 91: Global Tuberculosis Vaccine Treatment Revenue Market Share by Region (2027-2032)
- Table 92: North America Tuberculosis Vaccine Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 93: North America Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose)
- Table 94: North America Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose)
- Table 95: North America Tuberculosis Vaccine Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 96: North America Tuberculosis Vaccine Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 97: Europe Tuberculosis Vaccine Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 98: Europe Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose)
- Table 99: Europe Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose)
- Table 100: Europe Tuberculosis Vaccine Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 101: Europe Tuberculosis Vaccine Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 102: Asia Pacific Tuberculosis Vaccine Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 103: Asia Pacific Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose)
- Table 104: Asia Pacific Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose)
- Table 105: Asia Pacific Tuberculosis Vaccine Treatment Revenue by Country (2021-2026) & (US\$ Million)

- Table 106: Asia Pacific Tuberculosis Vaccine Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 107: South America Tuberculosis Vaccine Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: South America Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose)
- Table 109: South America Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose)
- Table 110: South America Tuberculosis Vaccine Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: South America Tuberculosis Vaccine Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Middle East and Africa Tuberculosis Vaccine Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Middle East and Africa Tuberculosis Vaccine Treatment Sales by Country (2021-2026) & (K Dose)
- Table 114: Middle East and Africa Tuberculosis Vaccine Treatment Sales by Country (2027-2032) & (K Dose)
- Table 115: Middle East and Africa Tuberculosis Vaccine Treatment Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Middle East and Africa Tuberculosis Vaccine Treatment Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: Global Tuberculosis Vaccine Treatment Sales by Type (2021-2026) & (K Dose)
- Table 118: Global Tuberculosis Vaccine Treatment Sales by Type (2027-2032) & (K Dose)
- Table 119: Global Tuberculosis Vaccine Treatment Sales Market Share by Type (2021-2026)
- Table 120: Global Tuberculosis Vaccine Treatment Sales Market Share by Type (2027-2032)
- Table 121: Global Tuberculosis Vaccine Treatment Revenue by Type (2021-2026) & (US\$ Million)
- Table 122: Global Tuberculosis Vaccine Treatment Revenue by Type (2027-2032) & (US\$ Million)
- Table 123: Global Tuberculosis Vaccine Treatment Revenue Market Share by Type (2021-2026)
- Table 124: Global Tuberculosis Vaccine Treatment Revenue Market Share by Type (2027-2032)
- Table 125: Global Tuberculosis Vaccine Treatment Price by Type (2021-2026) & (USD/K Dose)
- Table 126: Global Tuberculosis Vaccine Treatment Price by Type (2027-2032) & (USD/K Dose)
- Table 127: Global Tuberculosis Vaccine Treatment Sales by Application (2021-2026) & (K Dose)
- Table 128: Global Tuberculosis Vaccine Treatment Sales by Application (2027-2032) & (K Dose)
- Table 129: Global Tuberculosis Vaccine Treatment Sales Market Share by Application (2021-2026)
- Table 130: Global Tuberculosis Vaccine Treatment Sales Market Share by Application (2027-2032)
- Table 131: Global Tuberculosis Vaccine Treatment Revenue by Application (2021-2026) & (US\$ Million)
- Table 132: Global Tuberculosis Vaccine Treatment Revenue by Application (2027-2032) & (US\$ Million)
- Table 133: Global Tuberculosis Vaccine Treatment Revenue Market Share by Application (2021-2026)
- Table 134: Global Tuberculosis Vaccine Treatment Revenue Market Share by Application (2027-2032)
- Table 135: Global Tuberculosis Vaccine Treatment Price by Application (2021-2026) & (USD/K Dose)
- Table 136: Global Tuberculosis Vaccine Treatment Price by Application (2027-2032) & (USD/K Dose)
- Table 137: Key Raw Materials
- Table 138: Raw Materials Key Suppliers
- Table 139: Tuberculosis Vaccine Treatment Distributors List
- Table 140: Tuberculosis Vaccine Treatment Customers List
- Table 141: Tuberculosis Vaccine Treatment Industry Trends
- Table 142: Tuberculosis Vaccine Treatment Industry Drivers
- Table 143: Tuberculosis Vaccine Treatment Industry Restraints
- Table 144: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Tuberculosis Vaccine Treatment Product Image
- Figure 5: Global Tuberculosis Vaccine Treatment Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Tuberculosis Vaccine Treatment Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Tuberculosis Vaccine Treatment Sales (2021-2032) & (K Dose)
- Figure 8: Global Tuberculosis Vaccine Treatment Average Price (USD/K Dose) & (2021-2032)
- Figure 9: Immune Vaccine Product Image
- Figure 10: Therapy Vaccine Product Image
- Figure 11: Self-Procurement Product Image
- Figure 12: UNICEF Product Image
- Figure 13: Other Product Image
- Figure 14: Global Tuberculosis Vaccine Treatment Revenue Share by Manufacturers in 2025
- Figure 15: Global Manufacturers of Tuberculosis Vaccine Treatment, Manufacturing Sites & Headquarters
- Figure 16: Global Top 5 and 10 Tuberculosis Vaccine Treatment Players Market Share by Revenue in 2025
- Figure 17: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 18: Global Tuberculosis Vaccine Treatment Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 19: Global Tuberculosis Vaccine Treatment Sales by Region in 2025
- Figure 20: Global Tuberculosis Vaccine Treatment Revenue by Region in 2025
- Figure 21: North America Tuberculosis Vaccine Treatment Market Size by Country in 2025
- Figure 22: North America Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2032)

- Figure 23: North America Tuberculosis Vaccine Treatment Revenue Market Share by Country (2021-2032)
- Figure 24: United States Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 25: Canada Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Mexico Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Europe Tuberculosis Vaccine Treatment Market Size by Country in 2025
- Figure 28: Europe Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2032)
- Figure 29: Europe Tuberculosis Vaccine Treatment Revenue Market Share by Country (2021-2032)
- Figure 30: Germany Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: France Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: U.K. Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: Italy Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Russia Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Spain Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Switzerland Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Sweden Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Poland Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Asia Pacific Tuberculosis Vaccine Treatment Market Size by Country in 2025
- Figure 41: Asia Pacific Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2032)
- Figure 42: Asia Pacific Tuberculosis Vaccine Treatment Revenue Market Share by Country (2021-2032)
- Figure 43: China Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Japan Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: South Korea Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: India Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Australia Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Taiwan Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Southeast Asia Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: South America Tuberculosis Vaccine Treatment Market Size by Country in 2025
- Figure 52: South America Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2032)
- Figure 53: South America Tuberculosis Vaccine Treatment Revenue Market Share by Country (2021-2032)
- Figure 54: Brazil Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: Argentina Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Chile Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Middle East and Africa Tuberculosis Vaccine Treatment Market Size by Country in 2025
- Figure 58: Middle East and Africa Tuberculosis Vaccine Treatment Sales Market Share by Country (2021-2032)
- Figure 59: Middle East and Africa Tuberculosis Vaccine Treatment Revenue Market Share by Country (2021-2032)
- Figure 60: Egypt Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: South Africa Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: Israel Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: Türkiye Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: GCC Countries Tuberculosis Vaccine Treatment Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Global Tuberculosis Vaccine Treatment Sales Market Share by Type (2021-2032)
- Figure 66: Global Tuberculosis Vaccine Treatment Revenue Market Share by Type (2021-2032)
- Figure 67: Global Tuberculosis Vaccine Treatment Price (USD/K Dose) by Type (2021-2032)
- Figure 68: Global Tuberculosis Vaccine Treatment Sales Market Share by Application (2021-2032)
- Figure 69: Global Tuberculosis Vaccine Treatment Revenue Market Share by Application (2021-2032)
- Figure 70: Global Tuberculosis Vaccine Treatment Price (USD/K Dose) by Application (2021-2032)
- Figure 71: Tuberculosis Vaccine Treatment Value Chain
- Figure 72: Tuberculosis Vaccine Treatment Production Mode & Process
- Figure 73: Direct Comparison with Distribution Share
- Figure 74: Distributors Profiles
- Figure 75: Tuberculosis Vaccine Treatment Industry Opportunities and Challenges